Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

NCT00506805 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: SNX-5422

Sponsor

Esanex Inc.

Collaborators

[object Object]
[object Object]